

Carla Spazzolini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7759654/carla-spazzolini-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

5,948
citations

23
h-index

41
g-index

41
ext. papers

7,002
ext. citations

10.8
avg, IF

4.43
L-index

#	Paper	IF	Citations
39	Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years Experience Provides Guidance for Management.. <i>JACC: Clinical Electrophysiology</i> , 2022 , 8, 281-294	4.6	2
38	Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare Variants. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003289	5.2	0
37	Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. <i>European Heart Journal</i> , 2021 , 42, 4743-4755	9.5	4
36	An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. <i>Circulation</i> , 2020 , 141, 429-439	16.7	15
35	Exercise Training-Induced Repolarization Abnormalities Masquerading as Congenital Long QT Syndrome. <i>Circulation</i> , 2020 , 142, 2405-2415	16.7	8
34	Mothers with long QT syndrome are at increased risk for fetal death: findings from a multicenter international study. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , 222, 263.e1-263.e11	6.4	18
33	Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. <i>European Heart Journal</i> , 2019 , 40, 2964-2975	9.5	61
32	From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. <i>European Heart Journal</i> , 2019 , 40, 1832-1836	9.5	41
31	The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?. <i>International Journal of Cardiology</i> , 2018 , 250, 139-145	3.2	22
30	SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. <i>European Heart Journal</i> , 2018 , 39, 2879-2887	9.5	18
29	Cardiac arrest and Brugada syndrome: Is drug-induced type 1 ECG pattern always a marker of low risk?. <i>International Journal of Cardiology</i> , 2018 , 254, 142-145	3.2	9
28	For neonatal ECG screening there is no reason to relinquish old Bazett's correction. <i>European Heart Journal</i> , 2018 , 39, 2888-2895	9.5	19
27	Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. <i>International Journal of Cardiology</i> , 2017 , 249, 268-273	3.2	46
26	Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. <i>Circulation</i> , 2016 , 134, 872-882	16.7	118
25	Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3S Untranslated Region of KCNQ1?. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 330-9		16
24	The genetics underlying acquired long QT syndrome: impact for genetic screening. <i>European Heart Journal</i> , 2016 , 37, 1456-64	9.5	108
23	Response to Letters Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation". <i>Circulation</i> , 2016 , 133, e366-7	16.7	2

22	Response by Crotti et al to Letter Regarding Article, "Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3SUntranslated Region of KCNQ1?". <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 581-582		10
21	Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. <i>Circulation</i> , 2015 , 131, 2185-93	16.7	174
20	Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients. <i>Heart Rhythm</i> , 2014 , 11, 126-32	6.7	26
19	Tumor necrosis factor- α predicts response to cardiac resynchronization therapy in patients with chronic heart failure. <i>Circulation Journal</i> , 2014 , 78, 2232-9	2.9	20
18	A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: validation of the 2013 diagnostic criteria. <i>Heart Rhythm</i> , 2014 , 11, 1176-83	6.7	25
17	Rat experimental model of myocardial ischemia/reperfusion injury: an ethical approach to set up the analgesic management of acute post-surgical pain. <i>PLoS ONE</i> , 2014 , 9, e95913	3.7	11
16	Vagal reflexes following an exercise stress test: a simple clinical tool for gene-specific risk stratification in the long QT syndrome. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2515-24	15.1	42
15	Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2092-9	15.1	168
14	Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. <i>Circulation</i> , 2010 , 122, 1272-82	16.7	209
13	Mutation-specific risk in two genetic forms of type 3 long QT syndrome. <i>American Journal of Cardiology</i> , 2010 , 105, 210-3	3	22
12	Prevalence of the congenital long-QT syndrome. <i>Circulation</i> , 2009 , 120, 1761-7	16.7	649
11	High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". <i>Circulation</i> , 2009 , 119, 215-21	16.7	235
10	Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 832-7	15.1	70
9	All LQT3 patients need an ICD: true or false?. <i>Heart Rhythm</i> , 2009 , 6, 113-20	6.7	81
8	Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 920-9	15.1	88
7	The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. <i>Circulation</i> , 2007 , 116, 2366-75	16.7	130
6	Cost-effectiveness of neonatal ECG screening for the long QT syndrome. <i>European Heart Journal</i> , 2006 , 27, 1824-32	9.5	101
5	The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. <i>Circulation</i> , 2006 , 113, 783-90	16.7	274

4	Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. <i>Circulation</i> , 2005 , 112, 2602-10	16.7	150
3	Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. <i>Circulation</i> , 2004 , 109, 1826-33	16.7	503
2	Risk stratification in the long-QT syndrome. <i>New England Journal of Medicine</i> , 2003 , 348, 1866-74	59.2	1090
1	Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. <i>Circulation</i> , 2001 , 103, 89-95	16.7	1363